Department of Medicine Saint Vincent Hospital Worcester, MA.
Immunohematology and Blood Transfusion, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Jolly Grant Dehradun, Uttarakhand, India. .
Acta Biomed. 2020 Nov 10;91(4):e2020175. doi: 10.23750/abm.v91i4.10681.
The outbreak of the coronavirus disease 2019 (COVID-19) has posed an unprecedented challenge to the health care communities across the globe. As of June 2, 2020, a total of 6,418,968 confirmed COVID-19 cases with 378,954 deaths have been reported. Different regions of the world have reported varying intensity of COVID-19 severity. The disease burden for COVID-19 depends on multiple factors like the local infection rate, susceptible population, mortality rate, and so on. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. As of today, there is a lack of definitive treatment options for COVID-19 pneumonia. In search of alternative options, few drugs are being tested for their efficacy and repurposing. Preliminary reports have shown positive outcomes with Remdesivir and tocilizumab, but this needs further confirmation. Recently, the therapeutic application of Convalescent Plasma therapy in critically ill patients suffering from COVID-19 has gained momentum. We hereby discuss the convalescent plasma as a potential therapeutic option, its challenges of finding the ideal donors, transfusion medicine responsibilities, and the current global experience with its use.
2019 年冠状病毒病（COVID-19）的爆发给全球医疗保健界带来了前所未有的挑战。截至 2020 年 6 月 2 日，共报告了 6418968 例确诊的 COVID-19 病例，其中 378954 例死亡。世界不同地区报告了 COVID-19 严重程度的不同强度。COVID-19 的疾病负担取决于多种因素，如当地感染率、易感人群、死亡率等。COVID-19 大流行是一场迅速演变的紧急情况，是定期辩论和深入研究的主题。截至今天，针对 COVID-19 肺炎还没有明确的治疗选择。为了寻找替代方案，一些药物正在测试其疗效和重新利用。初步报告显示瑞德西韦和托珠单抗有积极的效果，但这需要进一步证实。最近，恢复期血浆疗法在 COVID-19 重症患者中的治疗应用得到了关注。我们在此讨论恢复期血浆作为一种潜在的治疗选择，其寻找理想供体的挑战、输血医学的责任以及其在全球的使用现状。
